The crosstalk between PI3K/AKT/mTOR and RAS/RAF/MEK pathways is well-described in PCa, suggesting combination therapy inhibitors targeting both pathways may be required to prevent disease progression (39–41). This evidence concerns the gene AKT1 and posterior cortical atrophy.